Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459810 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00459810 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT00459810, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estradiol may kill prostate cancer cells that no longer respond to hormone therapy. Giving paclitaxel poliglumex together with estradiol may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel poliglumex together with estradiol works in treating patients with stage IV prostate cancer.
Interventions
- DRUG paclitaxel poliglumex
- DRUG transdermal estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00459810
The ClinicalTrials.gov registry entry for NCT00459810 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel poliglumex is the first listed.
NCT00459810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00459810 about?
NCT00459810 is a clinical study titled "Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estradiol may kill prostate cancer cells that no longer respond to hormone therapy. Giving paclitaxel poliglu...
What is the current status of trial NCT00459810?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-02. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00459810?
The interventions under investigation include: paclitaxel poliglumex (DRUG), transdermal estradiol (DRUG).
Who is sponsoring clinical trial NCT00459810?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.